Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Teva Shows Long-Term Safety of Deutetrabenazine For Tardive Dyskinesia
Details : FDA has approved Teva's AUSTEDO XR (deutetrabenazine,vmat2 inhibitor) extended-release tablets as a once-daily treatment option for adults with tardive dyskinesia and Huntington’s disease chorea.
Product Name : Austedo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 23, 2024
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Teva’s AUSTEDO® XR Approved as Once-Daily Treatment for Tardive Dyskinesia
Details : FDA has approved Teva's AUSTEDO XR (deutetrabenazine,vmat2 inhibitor) extended-release tablets as a once-daily treatment option for adults with tardive dyskinesia and Huntington’s disease chorea.
Product Name : Austedo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 29, 2024
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Partnership
Teva and Jiangsu Nhwa Partner to Promote AUSTEDO® Access in China
Details :
Product Name : Austedo
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 26, 2024
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Austedo XR (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia (TD) in adults and for the treatment of chorea associated with huntington’s...
Product Name : Austedo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 17, 2023
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AUSTEDO (deutetrabenazine) is the first and only vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia (TD) in adults and for the treatment of chorea associated with ...
Product Name : Austedo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2022
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AUSTEDO (deutetrabenazine) Tablets is first and only vesicular monoamine transporter 2 (VMAT2) inhibitor approved by U.S. Food and Drug Administration in adults for treatment of tardive dyskinesia and for treatment of chorea associated with Huntington’...
Product Name : Austedo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AUSTEDO (deutetrabenazine) safety findings were consistent with findings from the overall OLE study population (n=337), with no new safety concerns from long-term treatment.
Product Name : Austedo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2022
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AUSTEDO (deutetrabenazine) Tablets,is first and only vesicular monoamine transporter 2 inhibitor approved by U.S. Food and Drug Administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’...
Product Name : Austedo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 2/3 ARTISTS 1 and Phase 3 ARTISTS 2 failed to meet the primary endpoint of reduction in motor and phonic tics as assessed by the Total Tic Score of the Yale Global Tic Severity Scale.
Product Name : Austedo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 19, 2020
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
